Raymond James analyst Justin Jenkins maintains ONEOK (NYSE:OKE) with a Outperform and lowers the price target from $70 to $65.
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $60
HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $54 to $60.